Figure 4.

ACE inhibition prevented growth-induced glomerular failure in the AA-4E-BP1 model. The following protections were observed by ACE inhibitor treatment with enalapril (10 mg/kg per day in the drinking water): body weight gain was not changed (A); kidney weight gain was reduced (F); glomerular tuft volume was reduced (I); rate of podocyte detachment was reduced (D); reduction of podocyte number per glomerular tuft was prevented (K); reduction in podocyte density was prevented (L); the increase in podocyte cell volume was not significantly reduced (J); urine protein/creatinine ratio was reduced (C); percent of glomeruli with adhesions and amount of glomerulosclerosis were reduced (G, E1, and E2); decreased creatinine clearance was prevented (H); and systolic BP increase with age was prevented (B). Data shown as the mean±SEM. Glomerular tuft volume (μm³), mean podocyte volume (μm³), podocytes per tuft (n) and podocyte nuclear density (n per 106 μm³). *P<0.05, **P<0.01. ACE-i, angiotensin-converting enzyme inhibitor; Ccr, creatinine clearance; Cre, urine creatinine; W, weeks.